Clinical trials
4 active trials in Germany
Recruiting, about to start, or running now.
- Early Genetic Identification of Obesity NCT06239064
- CrescNet - Growth Monitoring Network NCT03072537
- Leipzig Adipose Tissue Childhood Cohort NCT02208141
Updated
Reviewed by Chandani Patel
Germany Childhood Obesity Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$135.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $53.9 Mn | — | — |
| 2025 (base) | $61.4 Mn | +$7.4 Mn | — |
| 2026 (forecast) | $69.9 Mn | +$8.5 Mn | +13.8% |
| 2027 (forecast) | $79.5 Mn | +$9.6 Mn | +29.5% |
| 2028 (forecast) | $90.5 Mn | +$11.0 Mn | +47.4% |
| 2029 (forecast) | $103.0 Mn | +$12.5 Mn | +67.7% |
| 2030 (forecast) | $117.2 Mn | +$14.2 Mn | +90.9% |
| 2031 (forecast) | $133.3 Mn | +$16.2 Mn | +117.2% |
| 2032 (forecast) | $151.7 Mn | +$18.4 Mn | +147.2% |
| 2033 (forecast) | $172.7 Mn | +$20.9 Mn | +181.3% |
| 2034 (forecast) | $196.5 Mn | +$23.8 Mn | +220.1% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $61.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $196.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 13.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, age and end user (see all) |
| Key players | Novo Nordisk A/S, Eli Lilly and Company, Rhythm Pharmaceuticals, Kurbo (WW International), Teladoc Health (see all) |
| Regulator in Germany | BfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026. |
| Active clinical trials | 4 in GermanySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Childhood obesity treatment includes family programs, nutrition support, medicines and, for some teens, surgery to help children reach a healthier weight.
Key segments of the childhood Obesity Treatment market include treatment (Lifestyle and Behavioral Programs, Medication and Bariatric Surgery) and age (Children 6-11 and Adolescents 12-17).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the childhood Obesity Treatment market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the childhood Obesity Treatment market. Long-term safety data and lifestyle support are still needed for many patients.
The childhood Obesity Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.[2] ClinicalTrials.gov lists 4 studies on Childhood Obesity Treatment that are recruiting, active or about to start in Germany.[3] Obesity (adults): 20.6% of adults in 2024, the latest WHO figure for Germany.[4]
[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 21 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for childhood Obesity Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.
What doctors and scientists are doing in Childhood Obesity Treatment right now, from free public sources.
4 active trials in Germany
Recruiting, about to start, or running now.
20.6 % of adults
Obesity (adults), Germany, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
From our blog
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany
Germany
Germany
Germany
Healthcare Services · Germany
Medical Devices · Germany
Medical Devices · Germany
Medical Devices · Germany
Medical Devices · Germany
Healthcare Services · Germany